Christian S. Schade
2021
In 2021, Christian S. Schade earned a total compensation of $3.2M as Chairman and Chief Executive Officer at Aprea Therapeutics, a 17% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $265,225 |
|---|---|
| Option Awards | $1,444,310 |
| Salary | $530,450 |
| Stock Awards | $993,000 |
| Total | $3,232,985 |
Schade received $1.4M in option awards, accounting for 45% of the total pay in 2021.
Schade also received $265.2K in non-equity incentive plan, $530.5K in salary and $993K in stock awards.
Rankings
In 2021, Christian S. Schade's compensation ranked 4,136th out of 12,415 executives tracked by ExecPay. In other words, Schade earned more than 66.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,136 out of 12,415 | 67th |
Division Manufacturing | 1,704 out of 5,508 | 69th |
Major group Chemicals And Allied Products | 704 out of 2,378 | 70th |
Industry group Drugs | 626 out of 2,099 | 70th |
Industry Pharmaceutical Preparations | 440 out of 1,549 | 72nd |
Source: SEC filing on June 10, 2022.
Schade's colleagues
We found three more compensation records of executives who worked with Christian S. Schade at Aprea Therapeutics in 2021.
News
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020